(NASDAQ: LVTX) Lava Therapeutics Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.24%.
Lava Therapeutics Nv's earnings in 2025 is -$33,004,651.On average, 2 Wall Street analysts forecast LVTX's earnings for 2025 to be -$33,013,145, with the lowest LVTX earnings forecast at -$43,929,843, and the highest LVTX earnings forecast at -$22,096,448. On average, 2 Wall Street analysts forecast LVTX's earnings for 2026 to be -$13,152,648, with the lowest LVTX earnings forecast at -$13,941,806, and the highest LVTX earnings forecast at -$12,363,489.
In 2027, LVTX is forecast to generate -$12,626,542 in earnings, with the lowest earnings forecast at -$12,626,542 and the highest earnings forecast at -$12,626,542.